WO2012132747A1 - Composition liquide pour la cavité buccale et procédé d'ajout stable de composants à la composition - Google Patents

Composition liquide pour la cavité buccale et procédé d'ajout stable de composants à la composition Download PDF

Info

Publication number
WO2012132747A1
WO2012132747A1 PCT/JP2012/055170 JP2012055170W WO2012132747A1 WO 2012132747 A1 WO2012132747 A1 WO 2012132747A1 JP 2012055170 W JP2012055170 W JP 2012055170W WO 2012132747 A1 WO2012132747 A1 WO 2012132747A1
Authority
WO
WIPO (PCT)
Prior art keywords
component
composition
plaque
blended
liquid oral
Prior art date
Application number
PCT/JP2012/055170
Other languages
English (en)
Japanese (ja)
Inventor
尚子 川口
Original Assignee
ライオン株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライオン株式会社 filed Critical ライオン株式会社
Priority to CN201280016778.0A priority Critical patent/CN103458864B/zh
Priority to KR1020137022621A priority patent/KR101936969B1/ko
Publication of WO2012132747A1 publication Critical patent/WO2012132747A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients

Definitions

  • the present invention has an excellent effect of suppressing the adhesion of dental plaque to the tooth surface and the ability to sterilize mutans bacteria in dental plaque, and has improved appearance stability (no lip) and good palatability, and does not contain ethanol.
  • the present invention relates to a liquid oral composition and a method for stabilizing and blending ingredients into the composition.
  • Plaque suppression is important for the prevention of periodontal disease and caries, and oral compositions containing a bactericidal agent are widely used for the purpose of plaque suppression.
  • a bactericidal agent are widely used for the purpose of plaque suppression.
  • cationic fungicides are widely used because they have bactericidal effects on oral bacteria, plaque-inhibiting effects, and gingivitis improving effects.
  • hydroxyethyl cellulose dimethyl diallylammonium chloride has a property of being easily adsorbed on the tooth surface, and a liquid oral composition capable of effectively suppressing plaque formation using this is disclosed in Patent Document 1 (Japanese Patent Laid-Open No. 2001-2001). No. 64137).
  • Patent Document 2 Japanese Patent Document 1; JP 2001-139442 A, Patent Document 4; JP 2001-2001). 139443.
  • a technology that stably mixes a cationic bactericide and hydroxyethyl cellulose dimethyl diallylammonium chloride into a liquid formulation that does not contain ethanol ensures appearance stability, and achieves both the effects of both components and the preference of the formulation. Is desired.
  • the present invention has been made in view of the above circumstances, and is excellent in anti-plaque adhesion and sterilizing ability against mutans bacteria in plaque, and has improved appearance stability and good palatability.
  • An object of the present invention is to provide a liquid oral composition that does not contain it, and a method for stabilizing and blending ingredients into the composition.
  • the present inventor has formulated (A) a cationic bactericidal agent and (B) hydroxyethyl cellulose dimethyl diallylammonium chloride into a liquid oral composition substantially free of ethanol.
  • (C) Anethole is blended such that (C) component / [(A) component + (B) component] is in a mass ratio of 0.1 to 10, and (D) polyhydric alcohol and / or ( E)
  • a nonionic surfactant it has excellent anti-plaque effect on plaque adhesion and sterilizing ability of mutans bacteria in plaque, and also suppresses the occurrence of orientation of the preparation and improves the appearance stability over time. It has been found that a liquid preparation with high appearance stability and good palatability can be obtained, and the present invention has been made.
  • the present applicant has formulated a liquid oral composition containing substantially no ethanol, a cationic disinfectant and a cationized cellulose, and a blend of propylene glycol, polyoxyethylene hydrogenated castor oil, and paraoxybenzoic acid ester.
  • Japanese Patent Application No. 2010-280009 Japanese Patent Application No. 2011-148770 shows that the composition for oral cavity is excellent in the effect of suppressing the adhesion of plaque and the sterilizing ability of mutans bacteria in the plaque, as well as the antiseptic power and appearance stability of the preparation. Proposed).
  • This composition for liquid oral cavity is excellent in appearance stability (no tilt) after storage at 5 ° C. for 1 month.
  • Anethole is known to be used as a fragrance in oral compositions, but is effective for stabilizing and blending cationic bactericides and hydroxyethylcellulose dimethyl diallylammonium chloride into liquid oral compositions that do not contain ethanol, It is a new finding of the present inventor that high appearance stability with almost no orientation can be secured even after storage at 50 ° C. for 1 month, and that a liquid preparation having the above-mentioned special effects can be obtained.
  • the present invention provides the following liquid oral composition and a method for stabilizing and blending ingredients into the composition.
  • a liquid oral composition substantially free of ethanol is blended with (A) a cationic fungicide and (B) hydroxyethyl cellulose dimethyl diallylammonium chloride, and (C) anethole is added to component (C) / [(A).
  • Component + (B) component] is used in a mass ratio of 0.1 to 10, and (D) a polyhydric alcohol and / or (E) a nonionic surfactant is blended.
  • Liquid oral composition is used in a mass ratio of 0.1 to 10
  • D a polyhydric alcohol and / or (E) a nonionic surfactant is blended.
  • a liquid oral composition substantially free of ethanol is blended with (A) a cationic fungicide and (B) hydroxyethyl cellulose dimethyl diallylammonium chloride, and (C) anethole is added to component (C) / [(A).
  • Component + (B) component] is used in a range of 0.1 to 10 as a mass ratio, and (D) a polyhydric alcohol and / or (E) a nonionic surfactant is blended, A method of stabilizing and blending the components (A) and (B) in the composition.
  • a liquid oral composition substantially free of ethanol having excellent anti-plaque adhesion effect and sterilizing ability of mutans bacteria in dental plaque, improved appearance stability and good palatability Can be provided.
  • the liquid oral composition of the present invention comprises (A) a cationic fungicide, (B) hydroxyethylcellulose dimethyl diallylammonium chloride, (C) anethole, (D) a polyhydric alcohol and / or (E) a nonionic surfactant. Contains agents.
  • the cationic fungicide of the component (A) is an active ingredient for suppressing adhesion of plaque to the tooth surface and sterilizing mutans bacteria in the plaque.
  • Specific examples include cetylpyridinium chloride, benzethonium chloride, and benzalkonium chloride. One of these can be used alone, or two or more can be used in combination. Of these, cetylpyridinium chloride is preferred in terms of bactericidal power, handling properties and usability.
  • the blending amount of the cationic fungicide as component (A) is 0.01 to 0.1% (mass) of the whole composition from the viewpoint of suppressing adhesion of plaque to the tooth surface and sterilizing ability of mutans bacteria in the plaque. %. The same shall apply hereinafter.), In particular, 0.02 to 0.05% is preferable. If it is less than 0.01%, the effect of suppressing the adhesion of plaque to the tooth surface and the sterilizing ability of mutans bacteria in the plaque may not be satisfactorily exhibited. If it exceeds 0.1%, astringent taste, bitter taste, and off-flavor derived from the cationic fungicide may occur.
  • (B) Hydroxyethyl cellulose dimethyl diallylammonium chloride is a cationic polymer, and is blended as an active ingredient for suppressing adhesion of plaque to the tooth surface.
  • the component (B) together with the cationic germicide of the component (A) the effect of suppressing the adhesion of plaque to the tooth surface can be improved, and the mutans bacteria in the plaque can be effectively sterilized, By combining both effects, a high plaque formation inhibitory effect is achieved.
  • a commercially available product can be used as hydroxyethyl cellulose dimethyl diallylammonium chloride, and examples thereof include the following.
  • ⁇ Cell coat L-200 (manufactured by Akzo Nobel): Nitrogen content 0.1-3%, 2% aqueous solution viscosity 30-3,000 mPa ⁇ s (BH Brookfield viscometer, rotor No. 2, 20 revolutions, 21 ° C., measurement time 1 minute)
  • ⁇ Cell coat H-100 (manufactured by Akzo Nobel): Nitrogen content is 1.0%, 2% aqueous solution viscosity is 500-2,750 mPa ⁇ s (BH type Brookfield viscometer, rotor No. 2, 20 revolutions, 21 ° C., measuring time 1 minute)
  • the blending amount of component (B) hydroxyethylcellulose dimethyl diallylammonium chloride is preferably 0.005 to 0.5%, particularly 0.01 to 0.05% of the total composition. If it is less than 0.005%, the plaque adhesion inhibiting effect may not be satisfactorily exhibited. If it exceeds 0.5%, orientation may occur and appearance stability (no orientation) may be impaired, and astringency, bitterness, and off-taste derived therefrom may occur, resulting in a decrease in the feeling of use.
  • Component (C) Anethole is blended as a stabilizer.
  • orientation can be suppressed over time and appearance stability can be improved, and the feeling of use (astringency, bitterness, tastelessness) can also be improved.
  • the blending amount of anethole is preferably 0.01 to 0.2%, particularly preferably 0.01 to 0.1% of the whole composition. If the blending amount is less than 0.01%, the appearance stability (no tilt) may not be satisfactorily improved. In addition, the feeling of use (astringency, bitterness, tastelessness) may not be improved. If it exceeds 0.2%, the appearance stability (no tilt) may be impaired, and the feeling of use (taste) may be reduced.
  • component (C) / [component (A) + component (B)] is 0.1 to 10, and preferably 0.2 to 2, as a mass ratio.
  • (C) By mix
  • (A) and (B) component can be stabilized and mix
  • (D) and (E) component may mix
  • Examples of the (D) polyhydric alcohol include propylene glycol, glycerin, xylitol, sorbit, polyethylene glycol such as ethylene glycol and polyethylene glycol 400, polypropylene glycol, malt, lactit, and the like. A mixture of more than one can be used.
  • (E) As a nonionic surfactant what is normally mix
  • polyoxyethylene hydrogenated castor oil having an average addition mole number of ethylene oxide of 60 to 100 moles, an alkyl group having 16 (cetyl) to 18 (stearyl) carbon atoms and an average addition mole number of ethylene oxide of 20 to 40 moles.
  • polyoxyethylene hydrogenated castor oil is preferable from the viewpoint of sufficiently exerting the adhesion inhibitory effect of plaque on the tooth surface and the sterilizing ability of mutans bacteria in the plaque, and the appearance stability (no orientation),
  • ethylene oxide having an average added mole number of 60 to 100 moles is preferred. When the average added mole number of ethylene oxide is less than 60 moles, orientation may occur in a 50 ° C. stored product and appearance stability (no orientation) may be impaired, and those exceeding 100 moles are generally not commercially available.
  • NIKKOL HCO Polyoxyethylene hydrogenated castor oil
  • Emalex HC system manufactured by Nihon Emulsion Co., Ltd.
  • UNIOX HC system manufactured by NOF Corporation
  • the nonionic surfactant (E) When the nonionic surfactant (E) is blended, it is preferable to add 0.3 to 2%, particularly 0.5 to 1% of the whole composition. If it is less than 0.3%, the appearance stability (no orientation) may not be improved. If it exceeds 2%, the adhesion of dental plaque to the tooth surface and the ability to sterilize mutans bacteria in the plaque will be satisfactorily exhibited. May not be. Further, the feeling of use may be reduced.
  • the liquid oral composition of the present invention can be prepared and applied as a mouthwash, a mouth freshener, a liquid dentifrice used by brushing with a toothbrush, a dentifrice gel, etc. Suitable as an agent.
  • an appropriate known arbitrary component can be blended in addition to the above components within a range not impairing the effects of the present invention.
  • wetting agents, thickeners, preservatives, sweeteners, fragrances other than component (C), surfactants other than component (E), active ingredients other than components (A) and (B), colorants, pH A regulator or the like can be added.
  • polishing agent can be added.
  • the thickener include xanthan gum, sodium alginate, polyvinyl alcohol, hydroxyethyl cellulose, carrageenan, carboxymethyl cellulose sodium, polyvinyl pyrrolidone and the like.
  • the blending amount of these thickeners is usually 0 to 3% of the whole composition.
  • Examples of the preservative include parabens such as sodium benzoate, methyl paraben, ethyl paraben, propyl paraben, and butyl paraben, cetylpyridinium chloride, alkyldiaminoethylglycine hydrochloride, potassium sorbate, and the like.
  • Examples of the sweetening agent include saccharin, saccharin sodium, steviosite, sucralose, reduced palatinose, erythritol, aspartame and the like.
  • Perfumes other than anethole such as peppermint oil, spearmint oil, eucalyptus oil, wintergreen oil, clove oil, thyme oil, sage oil, cardamom oil, rosemary oil, marjoram oil, lemon oil, nutmeg oil, lavender oil
  • Natural essential oils such as paracres oil, and l-menthol, l-carvone, cinnamic aldehyde, orange oil, 1,8-cineole, methyl salicylate, eugenol, thymol, linalool, limonene, menthone, menthyl acetate, citral, camphor,
  • Perfume ingredients contained in the above natural essential oils such as borneol, pinene, spiranthol, etc., as well as ethyl acetate, ethyl butyrate, isoamyl acetate, hexanal, hexenal, methyl anthranilate,
  • anionic surfactants such as sodium lauryl sulfate, lauroylmethyl taurine, acylamino acid salts, sodium dodecylbenzenesulfonate, Anionic surfactants such as ⁇ -sulfo fatty acid alkyl ester sodium and alkyl phosphate ester salts, betaine acetate type amphoteric surfactants such as alkyldimethylaminoacetic acid betaine and fatty acid amidopropyldimethylaminoacetic acid betaine, N-fatty acid acyl- Examples include imidazoline type amphoteric surfactants such as N-carboxymethyl-N-hydroxyethylethylenediamine salt, and amino acid type surfactants such as N-fatty acid acyl-L-alginate salts.
  • the blending amount is usually 0 to 5%, particularly preferably
  • the active ingredient examples include bactericides such as chlorhexidine hydrochloride and alkyldiaminoethylglycine hydrochloride, anti-inflammatory agents such as tranexamic acid, epsilon-aminocaproic acid, allantoin, allantoinchlorohydroxyaluminum, allantoindihydroxyaluminum, dextranase, amylase, Enzymes such as protease, mutanase, lysozyme, lytic enzyme, lytechenzyme, fluoride such as sodium fluoride, sodium monofluorophosphate, stannous fluoride, vitamin C such as azulene, lysozyme chloride, ascorbic acid, dihydrocholesterol , Glycyrrhetin salts, Glycyrrhetinic acids, Hydrocholesterol, Chlorophyll, Copper chlorophyllin sodium, Thyme, Ogon, Clove, Hamamelis It
  • a highly safe water-soluble pigment such as Blue No. 1, Green No. 3, Yellow No. 4, Red No. 105
  • pH adjusters include phthalic acid, phosphoric acid, citric acid, succinic acid, acetic acid, fumaric acid, malic acid, carbonic acid and their potassium salts, sodium salts or ammonium salts, ribonucleic acid and salts thereof, sodium hydroxide, etc. 1 type or 2 or more types can be used, and what combined phosphoric acid and a citric acid, and those sodium salts is especially preferable.
  • the liquid oral composition of the present invention preferably adjusts the pH at 25 ° C. to 5.5 to 8.5, and sodium dihydrogen phosphate and sodium monohydrogen phosphate as pH adjusters in the vicinity thereof.
  • a combination of citric acid and sodium citrate can be used.
  • the compounding quantity can be 60% or more, especially 70% or more.
  • the liquid oral composition of the present invention is substantially free of ethanol.
  • “substantially free of ethanol” means that the amount of ethanol in the composition is preferably 100 ppm or less, more preferably 50 ppm or less, particularly preferably 10 ppm or less, based on the total composition. The value is 0 ppm.
  • the liquid oral composition of the present invention contains no ethanol. However, since the raw material-derived ethanol may be contained in a small amount in the fragrance compounded in the composition, these reasons are taken into consideration. In addition to ethanol contained in trace amounts in perfume and the like, it does not contain ethanol.
  • Liquid oral compositions having the compositions shown in Tables 1 to 4 were prepared by a conventional method and evaluated as follows. The results are shown in Tables 1 to 4.
  • Evaluation criteria for plaque adhesion suppression effect A: Average value of a value is less than 5 ⁇ : Average value of a value is 5 or more and less than 7.5 ⁇ : Average value of a value is 7.5 or more and less than 10 ⁇ : Average value of a value is 10 or more
  • a hydroxyapatite disk (diameter 7 mm ⁇ height 3.5 mm) as an attachment carrier was attached to a rotating disk (rotated at about 80 rpm) in the culture tank, and dental plaque was artificially formed on the surface thereof.
  • the culture by the above method was carried out for 14 days, and the following treatment was carried out for the latter 7 days. That is, 3 times a day, the hydroxyapatite disk to which plaque adheres is taken out of the culture tank, each is transferred to each petri dish (diameter 25 mm ⁇ height 14 mm), and the test composition 5 g (Example and Comparative Example) is used for 30 seconds. Soaked.
  • the plaque was transferred to a test tube (diameter 13 mm ⁇ 100 mm) to which 4 mL of physiological saline was added in order to evaluate the bactericidal activity of mutans bacteria in the plaque of the test composition.
  • ultrasonic disruption 200 ⁇ A output for 10 seconds
  • serial dilution 10-fold dilution for 6 stages
  • the plate medium was anaerobically cultured (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% hydrogen) until colonies could be confirmed with the naked eye. After counting the number of colonies in each plate medium, the number of viable bacteria was calculated. Further, as a control, the same treatment was performed using purified water instead of the test composition, and the number of viable bacteria in the plaque was calculated. The ratio of the viable count of those treated with each test composition when the viable count of those treated with purified water was taken as 100% was measured and indicated by the following criteria. Evaluation criteria: ⁇ : Number of remaining viable bacteria less than 1% ⁇ : Number of remaining viable bacteria 1% or more and less than 10% ⁇ : Number of remaining viable bacteria 10% or more and less than 50% ⁇ : Number of remaining viable bacteria 50% or more
  • THBHM composition expressed in mass per liter
  • Todd Hewit Broth Becton and Dickinso n company
  • 30g / L Hemin Sigma Aldrich
  • Vitamin K manufactured by Wako Pure Chemical Industries
  • Purified water Residue (Measured up so that the total amount becomes 1 L.)
  • Appearance stability evaluation method The sample (liquid oral composition) is filled into a colorless and transparent PET container (manufactured by Yoshino Kogyo Co., Ltd.) having a filled volume of 500 mL, and stored in a 50 ° C. constant temperature bath (manufactured by Sanyo Electric Co., Ltd., MPR-311) for one month. The appearance stability was visually determined according to the following criteria. Appearance stability evaluation criteria: A: No orientation is observed even when shaken. ⁇ : Although very small orientation is observed when shaken, it is at a level with no problem. ⁇ : Slight orientation is observed. X: Considerable orientation is recognized.
  • the main raw materials used in each example are as follows.
  • the perfume composition A is as shown in Tables 5 to 11.
  • Cetylpyridinium chloride manufactured by Wako Pure Chemical Industries, Ltd.
  • Benzethonium chloride Highamine 1622: Lonza Japan
  • Hydroxyethylcellulose dimethyldiallylammonium chloride (trade name Cellcoat L-200: manufactured by Akzo Nobel)
  • Leogard KGP O- [2-hydroxy-3- (trimethylammonio) propyl] hydroxyethylcellulose chloride: manufactured by Lion Corporation)
  • Anethole manufactured by Wako Pure Chemical Industries
  • Polyoxyethylene 100) hydrogenated castor oil (Nikko Chemicals)
  • Polyoxyethylene 60
  • hydrogenated castor oil (Nikko Chemicals)
  • Propylene glycol (Asahi Glass Co., Ltd.)
  • Glycerin 85%, Sakamoto Pharmaceutical Co., Ltd.)
  • compositions in which the components (A) and (B) are blended (C) anethole, or (D) a polyhydric alcohol and (E) a nonionic surfactant are lacking (Comparative Examples 3 and 5), C) When the ratio of anethole to the components (A) and (B) is inadequate (Comparative Example 4), neither occurrence of orientation can be suppressed and appearance stability is inferior. Even if a known fragrance was blended, the orientation could not be suppressed.
  • the composition of the present invention (Example) is excellent in plaque adhesion inhibiting effect and sterilizing effect of mutans bacteria in plaque, and has a good appearance with almost no orientation even when stored at 50 ° C. for 1 month. It turned out that it became stable, and also there was no astringency, bitterness, and unpleasant taste, and the feeling of use was also good.
  • liquid oral compositions of the following formulation examples were similarly prepared and evaluated. These compositions were excellent in plaque adhesion inhibitory effect, sterilizing ability of mutans bacteria in plaque, appearance stability and feeling of use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition liquide pour la cavité buccale, qui est excellente en termes d'un effet d'inhibition de dépôt de la plaque dentaire et d'un effet bactéricide contre Streptococcus mutans dans la plaque dentaire, possède une plus grande stabilité de l'apparence et a bon goût. Ladite composition est en outre dépourvue d'éthanol. La composition liquide pour la cavité buccale est caractérisée en ce que (A) un bactéricide cationique et (B) un copolymère d'hydroxyéthyl cellulose et de chlorure de diméthyl diallylammonium sont ajoutés à une composition liquide pour la cavité buccale qui est sensiblement dépourvue d'éthanol ; (C) de l'anéthol est également utilisé à un rapport en poids du composant (C)/[composant (A) + composant (B)] qui se trouve dans une plage de 0,1 à 10 ; et (D) un alcool polyhydrique et/ou (E) un surfactant non ionique sont ajoutés. La présente invention concerne en outre un procédé d'ajout stable des composants (A) et (B) à la composition, les composants (A) et (B) étant ainsi ajoutés à la composition liquide pour la cavité buccale, le composant (C) est également utilisé dans une plage de (C)/[(A)+(B)] de 0,1 à 10 ; et les composants (D) et/ou (E) sont ajoutés.
PCT/JP2012/055170 2011-03-25 2012-03-01 Composition liquide pour la cavité buccale et procédé d'ajout stable de composants à la composition WO2012132747A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201280016778.0A CN103458864B (zh) 2011-03-25 2012-03-01 液体口腔用组合物以及稳定化混合该组合物中组分的方法
KR1020137022621A KR101936969B1 (ko) 2011-03-25 2012-03-01 액체 구강용 조성물 및 그 조성물에 성분을 안정화 배합하는 방법

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011067845A JP5853387B2 (ja) 2011-03-25 2011-03-25 液体口腔用組成物及び該組成物へ成分を安定化配合する方法
JP2011-067845 2011-03-25

Publications (1)

Publication Number Publication Date
WO2012132747A1 true WO2012132747A1 (fr) 2012-10-04

Family

ID=46930494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/055170 WO2012132747A1 (fr) 2011-03-25 2012-03-01 Composition liquide pour la cavité buccale et procédé d'ajout stable de composants à la composition

Country Status (5)

Country Link
JP (1) JP5853387B2 (fr)
KR (1) KR101936969B1 (fr)
CN (1) CN103458864B (fr)
MY (1) MY164603A (fr)
WO (1) WO2012132747A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9192565B2 (en) 2011-11-09 2015-11-24 Colgate-Palmolive Company Alcohol-free mouthwash
WO2016089347A1 (fr) * 2014-12-01 2016-06-09 Colgate-Palmolive Company Augmentation de résistance aux microbes

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125841B2 (en) * 2013-02-26 2015-09-08 Johnson & Johnson Consumer Inc. Oral care compositions
JP6413815B2 (ja) * 2015-02-06 2018-10-31 ライオン株式会社 液体口腔用組成物
KR102337307B1 (ko) 2017-04-10 2021-12-09 (주)아모레퍼시픽 저자극성 구강용 조성물
JP7143198B2 (ja) * 2018-12-03 2022-09-28 サンスター株式会社 口腔用組成物
WO2021167845A1 (fr) * 2020-02-18 2021-08-26 Sunstar Americas, Inc. Composition de soin buccal

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001226244A (ja) * 1999-12-08 2001-08-21 Lion Corp 歯磨剤組成物
JP2002187829A (ja) * 1999-12-08 2002-07-05 Lion Corp 歯磨剤組成物
WO2007066497A1 (fr) * 2005-12-09 2007-06-14 Lion Corporation Composition de dentifrice
JP2008120753A (ja) * 2006-11-14 2008-05-29 Sunstar Inc 液体口腔用組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3890395A (en) * 1994-11-17 1996-06-17 Warner-Lambert Company Antimicrobial oral compositions
JPH11255629A (ja) * 1998-01-08 1999-09-21 Sunstar Inc 口腔用組成物
JP2001139442A (ja) * 1999-08-27 2001-05-22 Lion Corp 液体口腔用組成物
EP1236461A1 (fr) * 1999-12-08 2002-09-04 Lion Corporation Compositions de pate dentifrice
JP4985905B2 (ja) * 2005-07-29 2012-07-25 ライオン株式会社 液体口腔用組成物及びｌ−メントールの析出防止方法
JP5682283B2 (ja) * 2009-12-25 2015-03-11 ライオン株式会社 液体口腔用組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001226244A (ja) * 1999-12-08 2001-08-21 Lion Corp 歯磨剤組成物
JP2002187829A (ja) * 1999-12-08 2002-07-05 Lion Corp 歯磨剤組成物
WO2007066497A1 (fr) * 2005-12-09 2007-06-14 Lion Corporation Composition de dentifrice
JP2008120753A (ja) * 2006-11-14 2008-05-29 Sunstar Inc 液体口腔用組成物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9192565B2 (en) 2011-11-09 2015-11-24 Colgate-Palmolive Company Alcohol-free mouthwash
WO2016089347A1 (fr) * 2014-12-01 2016-06-09 Colgate-Palmolive Company Augmentation de résistance aux microbes
US10537506B2 (en) 2014-12-01 2020-01-21 Colgate-Palmolive Company Increasing micro-robustness

Also Published As

Publication number Publication date
KR101936969B1 (ko) 2019-01-09
CN103458864B (zh) 2016-08-17
JP5853387B2 (ja) 2016-02-09
KR20140007406A (ko) 2014-01-17
CN103458864A (zh) 2013-12-18
MY164603A (en) 2018-01-30
JP2012201632A (ja) 2012-10-22

Similar Documents

Publication Publication Date Title
JP5136797B2 (ja) イソプロピルメチルフェノール含有液体口腔用組成物
JP4591680B2 (ja) 液体口腔用組成物
CN107875031B (zh) 口腔生物膜除去剂以及口腔用组合物
JP4985905B2 (ja) 液体口腔用組成物及びｌ−メントールの析出防止方法
JP5853387B2 (ja) 液体口腔用組成物及び該組成物へ成分を安定化配合する方法
JP4957882B2 (ja) エタノール無配合洗口剤組成物
JP5729252B2 (ja) 口腔用組成物
JP6318487B2 (ja) 口腔用組成物
JP5359546B2 (ja) 液体口腔用組成物
WO2018194111A1 (fr) Agent d'élimination du biofilm buccal et composition buccale
JP4873154B2 (ja) 液体口腔用組成物
JP2010143843A (ja) 液体口腔用組成物
JP5682283B2 (ja) 液体口腔用組成物
CN107205899B (zh) 液体口腔用组合物
JP5729391B2 (ja) 歯周病原因菌の歯面付着抑制剤、口腔バイオフィルム形成抑制剤及び口腔用組成物
JP5682264B2 (ja) 口腔用組成物及び歯周病原因菌の歯面付着抑制剤
JP4952940B2 (ja) 液体口腔用組成物
WO2011077847A1 (fr) Composition liquide de type émulsion pour la cavité orale, et procédé de production de celle-ci
KR101773227B1 (ko) 치마제 조성물
JP2013203676A (ja) 口腔用組成物
CN109689016B (zh) 液体口腔用组合物
JP2013256466A (ja) 液体口腔用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12764783

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20137022621

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1301005319

Country of ref document: TH

122 Ep: pct application non-entry in european phase

Ref document number: 12764783

Country of ref document: EP

Kind code of ref document: A1